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Abstract
Objectives
Rett syndrome is an X linked dominant neurodevelopmental disorder 
which almost exclusively affects females. The syndrome is usually 
caused by mutations in MECP2 gene, which is a nuclear protein that 
selectively binds CpG dinucleotides in the genome. 
Materials & Methods
To provide further insights into the distribution of mutations in 
MECP2 gene, we investigated 24 females with clinical characters 
of Rett syndrome referred to Alzahra University Hospital in Isfahan, 
Iran during 2015-2017. We sequenced the entire MECP2 coding 
region and splice sites for detection of point mutations in this gene. 
Freely available programs including JALVIEW, SIFT, and PolyPhen 
were used to find out the damaging effects of unknown mutations. 
Results
Direct sequencing revealed MECP2 mutations in 13 of the 24 patients. 
We identified in 13 patients, 10 different mutations in MECP2 gene. 
Three of these mutations have not been reported elsewhere and are 
most likely pathogenic. 
Conclusion
Defects in MECP2 gene play an important role in pathogenesis 
of Rett syndrome. Mutations in MECP2 gene can be found in the 
majority of Iranian RTT patients. We failed to identify mutations 
in MECP2 gene in 46% of our patients. For these patients, further 
molecular analysis might be necessary. 
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Rett syndrome, is a severe X linked dominant 
neurodevelopmental disorder that predominantly 
affects females, and has been considered lethal to 
males (1, 2). 
Typically, this syndrome is characterized 
by apparently normal development during 
the first 6 months of life, followed by rapid 
deterioration with regression of social, motor, and 
communication skills (1). Clinical features also 
include microcephaly, seizures, stereotypical hand 
movements, scoliosis, ataxia, intellectual disability, 
and little or no verbal skills (3). Rett syndrome 
is usually due to mutations in the MECP2 gene, 
located on chromosome X (Xq28) and encodes 
a methyl-CpG binding protein 2 (MECP2) (1). 
MECP2 is a nuclear protein that selectively binds 
CpG dinucleotides in the mammalian genome and 
may act as a silencer of gene expression interacting 
with other proteins such as histone deacetylase 
complex and the transcriptional corepressor sin3A 
(4).
MECP2 gene has two protein isoform. Both 
isoforms contain five major domains: N-terminal 
domain (NTD), Methyl binding domain (MBD), 
Inter-Domain (ID), Transcription repression 
domain (TRD) and C-terminal domain (CTD) (5). 
The majority of Rett patients have mutations in 
exons 3 or 4, which encode the MECP2 functional 
domains, the MBD and the TRD domain, 
respectively (1).
To provide further insights into the spectrum and 
distribution of mutations in MECP2 gene, we 
performed sequencing of the entire MECP2 coding 
regions and splice sites in 24 female cases with 
clinical characteristics of Rett syndrome from the 
Iranian population.
Materials and Methods 
Molecular genetic analysis of MECP2 gene was 
carried out in 24 sporadic Iranian female patients 
with Rett syndrome referred to Alzahra University 
Hospital in Isfahan, Iran during 2015-2017. 
This study was approved by the Ethics Committee 
of Isfahan University of Medical Sciences and 
consent forms were obtained from all the patients’ 
parents.
27
Genetic Analysis of MECP2 Gene in Iranian Patients with Rett Syndrome
Iran J Child Neurol. Summer 2019 Vol. 13 No. 3
Clinical diagnosis was according to the diagnostic 
criteria (6). The patients had at least five of the 
necessary criteria proposed by the Rett syndrome 
Diagnostic Criteria Work Group (7) (Table 1). 
Clinical details of each patient were recorded by 
neurologists (Table 2).
We prepared genomic DNA from peripheral blood 
leukocytes of patients by the standard salting-out 
method (8). PCR was performed for exons 1, 2, 3, 
and 4 using primer pairs reported in Table 3. For 
exons 2, 3 and 4, PCR reactions were performed 
with Taq DNA polymerase kit (Feldan, Germany) 
in a final volume of 50 µl, using 5 µl band 
sharpener, 5 µl 10x Taq Buffer, 1 µl dNTP mix (10 
mM), 0.4 µl Taq DNA polymerase (5 U/μl), 2 µl of 
forward and reverse primer (10 pmole/μl) and 200 
ng of DNA. For the amplification of exon 1, a GC-
rich amplicon difficult to amplify, the optimization 
of the PCR protocol implied the use of the same 
components plus 5 µl of DMSO (5 M). Cycling 
parameters were 94 °C for 5 min, followed by 30 
cycles of 94 °C for 1 min, 63 °C for 1 min, 72 °C 
for 1 min and a final step of 72 °C for 10 min. 
All PCR products were visualized on 1% agarose 
gel and were sequenced on an ABI 3130 sequencer 
(Applied Biosystems, United Kingdom) with a 36-
cm capillary array and POP-4 polymer (Applied 
Biosystems). All the patients were sequenced for all 
five fragments. The obtained nucleotide sequences 
were compared to the reference sequence in Gene 
Bank (Ref Seq NC_000023.11) using BLAST and 
sequence variation was confirmed on both strands. 
All the sequence variations detected in this study 
were confirmed by a new sequencing performed 
from a newly amplified sample. In silico analysis 
was performed for novel mutations.
Results
Direct sequencing revealed MECP2 mutations in 
13 of the 24 patients. All the detected mutations 
were compared with RettBASE: MECP2 
variation database (http://mecp2.chw.edu.au/). 
The mutations include four missense mutations 
(A73D, R306C, T158M and R106W), two 
nonsense mutations (R168X and R255X), three 
deletions (R270fs, K286fs, K233fs) and one 
complex deletion/insertion (G237fs) based on 
the NM_004992.3 transcript (Table 4). Although 
the spectrum of mutations is very heterogeneous, 
mutations mainly occur in exon 4, which points to 
mutational hotspots in MECP2 gene. 
In order to find out the functional consequences of 
this new missense mutation, we performed in silico 
analyses with JALVIEW, SIFT (http://sift.jcvi.org/) 
and PolyPhen (http://genetics.bwh.harvard.edu/
pph2/). c.218 C>A is pathogenic. Multiple alignments 
of the sequences using Jalview showed that the 
amino acid position in exon 3 is physicochemically 
conserved in mammals (Figure 1).
28
Genetic Analysis of MECP2 Gene in Iranian Patients with Rett Syndrome
Iran J Child Neurol. Summer 2019 Vol. 13 No. 3
Table 1. Diagnostic criteria for Rett syndrome (14)
Necessary criteria
(1)Apparently normal prenatal and perinatal period
(2)Apparently normal psychomotor development through the first 6 months
(3)Normal head circumference at birth
(4)Deceleration of head growth between the ages of 5 months and 4 yr
(5)Loss of acquired purposeful hand skills between the ages of 6 and 30 months, temporally associated with 
communication dysfunction and social withdrawal
(6)Development of severely impaired expressive and receptive language, and presence of apparent severe 
psychomotor retardation.
(7)Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing and washing/rubbing 
automatisms appearing after purposeful hand skills are lost
(8)Appearance of gait apraxia and truncal apraxia/ataxia between ages 1 and 4 yr of age
(9)Diagnosis tentative until 2-5 yr of age
Table 2. Clinical features of Rett patients with MECP2 mutations. Clinical features were assigned +, - or 0 which is consistent with 












































1 3 year Classical + + - - + + + + + - + + +
2 11 year Classical + + - - + + + 0 + - - - -
3 7 year Atypical + + + - + + + - - + + + +
4 5 year Classical - + - - + - + + + - + - -
5 3.5 year Classical - + - - + + + + + + - - -
6 22 month Classical - + - - + + + + + + + + -
7 8 year Atypical + + - + - - + - - + + - +
8 4 year Classical + + + - + - + + + + + - -
9 6 year Atypical + - - + - - + - - + + + +
10 5.5 year Classical + + - - + + + + + - - + -
11 3.5 year Classical + - - - + + + - + - + - +
12 10 year Classical + - + + + - + - + + + + +
13 6 year Atypical + - - + - - + - - + + + +
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Table 3. The primers and PCR conditions designed for the analysis of the MECP2 gene
Exon Fragment Primers Product 
size(bp)
Tm(˚C)
Exon 1 Forward CAAGCCTAGGCCTTCACTTGCC 610 bp 66 ˚C
Reverse CATCCGCCAGCCGTGTCG
Exon 2 Forward AGTGTGTTTATCTTCAAAATGT 376 bp 63 ˚C
Reverse GTTATGTCTTTAGTCTTTGGG
Exon 3 Forward CTTGCATGTGGTGGGGGTC 590 bp 63 ˚C
Reverse AGTCATTTCAAGCACACCTGGTC
Exon 4 Exon 4a
Reverse




Forward CTGGGCGGAAAAGCAAGGAGAG 545 bp 63 ˚C
GTGATTTCAGTTAATCGGGAAGCTTTG
Table 4. Identified mutations of MECP2 gene
Patient Mutation in CDNA Mutation in 
amino acid
exon Domain Type of mutation Reference
1 c.218 C>A p.A73D 3 NTD Missense This study
2 c. 697-701del p.K233fs 4 TRD Frame shift This study
3 c.502 C>T p.R168X 4 ID Nonsense Hoffbuhr et al. (2001)
4 c. 856-859 del AAAG p.K286fs 4 TRD Frame shift Hoffbuhr et al. (2001)
5 c.916C>T p.R306C 4 TRD Missense Wan et al. (1999)
6 c.316C>T p.R106W 3 MBD Missense Amir et al. (1999)
7 c.709-751delinsAAG p.G237fs 4 TRD Frameshift This study
8 c.763C>T p.R255X 4 TRD Nonsense Amir et al. (1999);
9 c.502C>T p.R168X 4 ID Nonsense
10 c.916C>T p.R306C 4 TRD Missense
11 c.473C>T p.T158M 4 MBD Missense Amir et al. (1999)
12 c.916C>T p.R306C 4 TRD Missense















Figure 1. Analysis by Jalview showed that amino acid 73 is conserved in mammals 
 
Figure 1. Analysis by Jalview showed that amino acid 73 is conserved in mammals
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Discussion 
With the discovery of mutations in MECP2 gene, 
RTT became the first human disease to be caused 
by mutations in a gene encoding a factor that has 
role in the epigenetic silencing machinery (9).
In our study, three of the thirteen patients with 
MECP2 mutations had one of the nonsense 
mutations reported by Wan et al (9). Two of 
them had the R168X mutation, which encodes 
a truncated MECP2 protein containing only 
the MBD and lacking the TRD, the nuclear 
localization signal and the C-terminal region (11). 
Since the R168X mutation is within the last exon, 
between the MBD and TRD, it is not expected to 
cause nonsense-mediated decay; therefore, the 
truncated form of the protein may retain its ability 
to bind to 5-methyl CpG. However, as the nuclear 
localization signal (NLS) is within the TRD, the 
truncated protein lacking the NLS, may stay in 
the cytoplasm (9, 12). The other patient had the 
c.763C > T common mutation which substitutes 
the conserved arginine 255 (CGA) to a stop codon 
(TGA) creating a truncated MECP2 protein. This 
p.R255X nonsense mutation is located in TRD-
NLS of MECP2 protein (13). Six patients in this 
study had a missense mutation. The missense 
mutation R306C was found in 3 out of 13 patients 
(23%). The R306C mutation is located in the 
C-terminal part of the TRD and is the first missense 
mutation identified in the TRD (9). Amino acids 
269-309 of MECP2 are necessary for binding to 
the NCoR/SMRT co-repressor complex and loss 
of this connection gives rise to RTT. The R306C 
mutation, abolish the association between the 
NCoR/SMRT complex and MECP2 protein, which 
can cause Rett syndrome (14). 
The other missense mutation R106W causes an 
arginine to tryptophan amino acid change in the 
MBD domain. This amino acid substitution may 
reduce the initial binding to methylated DNA 
by more than 100-fold and lacks the ability to 
localize to heterochromatin domains and to repress 
transcription (15). This mutation is among the eight 
common mutations in MECP2 gene, which causes 
a full RTT phenotype in girls (1, 12, 16). The other 
patient had the T158M missense mutation which 
substitutes threonine, a hydrophobic amino acid, 
with a polar amino acid, methionine in the MBD 
of MECP2 protein. This change may affect the 
C-terminal stretch of MBD, thereby interfering 
with its function. MECP2 proteins with T158M 
mutation in MBD have only a two-fold decrease 
for methylated DNA. 
Four of our studied cases had a deletion or/and 
insertion, which two of them have been reported 
previously and two are possibly novel mutations. 
The first case had a small deletion of four bases 
AAAG at position 856-859 in exon four of 
MECP2 gene. This deletion leads to the K286 
frameshift mutation and a premature stop codon. 
This premature stop codon leads to the synthesis 
of a truncated MECP2 protein. Since this mutation 
is located in the TRD, it will probably affect the 
transcriptional repression activity of the MECP2 
protein (17). The second case had a single C base 
deletion at position 808 in exon 4, which causes 
a frameshift mutation in the TRD of the protein. 
In this study, we identified 3 novel mutations. 
The first one had a small deletion of five bases 
(AAGGC) in position 696. In the second novel 
mutation (c.709_751delinsAAG), 42 nucleotides 
were deleted and 3 nucleotides were inserted. Both 
of these create a frameshift mutation in the TRD 
of MECP2 protein. Since these mutations create 
truncated protein, they are most likely pathogenic.
The third novel mutation identified in this study 
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was a missense mutation. The A73D mutation 
substitutes alanine, a non-polar amino acid, with 
a polar amino acid, aspartic acid in the NTD of 
MECP2 protein. In order to assess the pathogenesis 
of this mutation, DNA samples from both parents 
were analyzed. None of the parents carried this 
mutation; therefore this missense mutation is a 
non-polymorphic variation and is most likely 
pathogenic.
So far, very few studies have been conducted on 
Rett syndrome in Iran. The existing reports were 
limited to the clinical signs in a few patients and 
a mutation in MECP2 in one patient with Rett 
syndrome (18-20). For the first time in Iran, we 
investigated 24 females with clinical characters 
of Rett syndrome from the Iranian population. We 
sequenced the entire MECP2 coding region and 
splice sites and identified in 13 out of 24 unrelated 
patients, 10 different mutations. 23.8% of patients 
with clinical characteristics of Rett syndrome had 
mutations in MECP2. Mutation detection rate 
varied among different studies which was between 
23-90% (4, 9, 10). In this study, 54% of patients 
had MECP2 mutations, which is similar to another 
study (9). Among the molecular defects reported 
in this study, four are missense mutations, two are 
nonsense mutations, three are deletions and one 
is a complex deletion/insertion. Mutations mainly 
occur in exon 4 and the multiple recurrences of 
R168X (two times) and R306C (three times), 
points to true mutational hotspots. These two 
recurring mutations account for 38% (5 of 13) of 
all mutation-positive cases. We described three 
novel mutations not reported previously and are 
most likely pathogenic. 
To date, more than 250 mutations have been 
identified in MECP2, although eight specific 
mutations (R106W, P152R, T158M, R168X, 
R255X, R270X, R288X, and R306C) are found in 
more than 60% of individuals with RTT (21, 22). 
Most of the mutations are C>T transitions, which 
are located in the MBD, TRD or ID. The high 
frequency of cytosine to thymidine transitions at 
CpG dinucleotides suggests that deamination of 
methylated cytosine is a prevalent cause of Rett 
syndrome (23). We have screened only for mutations 
in the coding region, and the promoter region was 
not screened, nor was DNA rearrangements or 
deletions. Even more, the conserved regions of 
3´UTR suggest that these sequences are important 
for post-transcriptional regulation of MECP2. It is 
acceptable that mutations in the 3´ UTR and the 
promoter region or maybe DNA rearrangements 
or deletions of MECP2 might be the underlying 
cause of Rett syndrome in those patients without 
any identified mutations (4, 24). Since not all 
patients studied so far carry mutations in MECP2 
gene, it is possible that this disorder is genetically 
heterogeneous. Although MECP2 plays a key role in 
Rett syndrome, other genes that might interact with 
MECP2 may also contribute to RTT development 
(25). Mutations within the CDKL5 and NTNG1 
gene have been reported in some patients with 
clinical characteristics that overlap with RETT 
syndrome (26). Recent reports have found another 
gene, FOXG1, to be highly associated with Rett 
syndrome (27). In our analysis, we failed to detect 
MECP2 mutations in 11 of the patients clinically 
classified as Rett cases. These cases have to be 
analyzed for mutations in other regions of MECP2 
or in other candidate genes.
Although the number of patients with identified 
MECP2 mutations was not enough for statistical 
analysis, we investigated a genotype-phenotype 
correlation. We first focused on patients with 
different MECP2 mutations and tried to find a 
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genotype-phenotype correlation, taking in to 
account the type of mutation and the position. 
An increase in phenotype severity was reported 
in nonsense mutations when compared with 
missense mutations; however, among different 
groups studied so far, the results of the phenotype-
genotype data have not been consistent (28). In our 
study, when the type of mutation was compared 
with the clinical features of the patient, no clear 
correlation was detected. In the next step, we 
examined the genotype/phenotype correlation in 
the group of patients with same MECP2 mutation. 
For this, we studied the patients with recurring 
R306C mutation. The clinical symptoms were 
variable in three patients with R306C mutation. 
This shows no specific correlation between R306C 
mutation and a significant phenotype. Likewise, 
a previous genotype/phenotype correlation study 
did not offer any definite data in groups of patients 
showing the same mutation (29). Generally 
speaking, correlation of specific RTT mutations 
with a significant clinical manifestation can be 
hindered by the heterogeneity of this disease, as, 
even between patients with the same MECP2 
mutation, symptoms vary greatly (14).
In conclusion, mutations in MECP2 are a common 
cause of Rett syndrome and mutations in MECP2 
gene can be found in the majority of Iranian 
RTT patients. Exon 4 of MECP2 gene should be 
sequenced first. If no mutations are found, other 
exons should also be screened.
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